Key clinical point: Overall survival improved by more than 20% in older adults with myelodysplastic syndrome who received allogeneic stem cell transplantation.
Major finding : Overall survival at 3 years was 47.9% for patients who received allogeneic hematopoietic cell transplantation compared to those who did not.
Study details: The data come from myelodysplastic syndrome patients with a median age of 66 years who were part of the prospective Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study 1102 ( NCT02016781) presented at the American Society of Hematology (ASH) 2020 virtual meeting.
Disclosures: Lead author Dr. Cutler disclosed serving as a consultant for Mesoblast, Generon, Medsenic, Jazz, Kadmon, and Incyte.
Source: Cutler C et al. ASH 2020.